Creative Biolabs isolates B. animalis from fecal samples, fermented dairy matrices, and other complex communities using anaerobic culturing, selective media, and high-throughput colony screening. We capture broad B. animalis diversity and pre-screen for traits such as SCFA production, carbohydrate use, and host origin to underpin proprietary strain portfolios.
Within the Bifidobacterium genus, differentiating B. animalis subsp. lactis from subsp. animalis is critical for regulatory positioning and label accuracy. We combine 16S rRNA sequencing, whole-genome sequencing (WGS), and in silico typing pipelines to deliver unambiguous B. animalis taxonomic assignment, strain-level fingerprints, and documentation aligned with GRAS/QPS expectations.
To reach the colon, B. animalis must withstand gastric acid, bile salts, osmotic shifts, and transient oxygen exposure. Using standardized acid-bile challenges, osmotic and oxidative stress assays, and simulated GI transit models, Creative Biolabs quantifies B. animalis survival and recovery kinetics, enabling data-driven selection of strains with robust colonization potential and industrially relevant resilience.
B. animalis has been linked to support of bowel function, digestive comfort, and immune modulation in multiple studies. Creative Biolabs designs B. animalis functional screening panels, including epithelial barrier integrity, pathogen inhibition, SCFA and lactate profiling, bile salt deconjugation, and host cell co-culture assays. These platforms help map mechanism-of-action (MoA) hypotheses and generate translational data packages for advanced product concepts.
As a strictly anaerobic species, B. animalis demands carefully controlled fermentation to reach high cell densities. Our bioprocess team optimizes media composition (carbon sources, nitrogen, growth factors), pH and temperature profiles, and redox management for B. animalis from shake flasks to lab-scale bioreactors, generating scalable feeding strategies, productivity metrics, and process transfer documentation for your internal or external manufacturers.
Translating B. animalis from fermentation to a stable product requires careful formulation. Creative Biolabs develops formats such as freeze-dried powders, capsules, and food-matrix integrations, evaluating protectants and encapsulation strategies to safeguard this oxygen-sensitive species from oxygen, moisture, heat, and mechanical stress during processing, storage, and distribution.
Maintaining label-claim viable counts over shelf life remains a central challenge for B. animalis products. We run real-time and accelerated stability studies under controlled temperature and humidity, tracking B. animalis viability, potency, and key quality attributes in your final format. The data support shelf-life claims, packaging selection, and formulation refinement for global markets.
B. animalis is recognized as suitable for EFSA’s QPS when strain identity and absence of acquired antibiotic resistance are confirmed. Creative Biolabs provides full safety profiling, including antimicrobial susceptibility, hemolysis testing, virulence and mobile-element screening, and genome-based annotation to support GRAS/QPS-aligned documentation.
